Concord Biotech EBITDA per Share

What does Concord Biotech do? Concord Biotech Ltd generates revenue through the research, development, manufacturing, and marketing of pharmaceutical products. The company produces active pharmaceutical ingredients (API) using fermentation and semi-synthetic processes, including Mycophenolate Mofetil, Cyclosporine, and Vancomycin Hydrochloride, among others. Finished formulations are sold in therapeutic segments such as immunosuppressants, anti-bacterial, oncology, and anti-fungal. The firm also develops API products like Polymyxin B and Fidaxomicin for future commercialization. Concord Biotech targets critical care, immunology, nephrology, and transplant medicine markets with its API and finished product portfolio. The company's R&D-driven approach focuses on developing new API products under development, including Doxorubicin, to expand its therapeutic offerings. Manufacturing capabilities for fermentation and semi-synthetic based products support the production of key pharmaceuticals for global healthcare needs. The firm's product range includes Mycophenolate Sodium, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, which are marketed in various therapeutic segments. These products are sold to healthcare providers and pharmaceutical distributors globally, supporting the company's growth in the biopharma industry. Concord Biotech is one of the most popular companies on Eulerpool.